Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855451 | 1.00 | NOD1 (0.52) | NOD1SLC6A5EPHX1TLR2FOLH1 | |
| SCHEMBL8466972 | 1.00 | NOD1 (0.52) | NOD1SLC6A5EPHX1TLR2FOLH1 | |
| SCHEMBL8760314 | 0.99 | NOD1 (0.54) | NOD1SLC6A5EPHX1TLR2ITGB3 | |
| SCHEMBL9716662 | 0.95 | NOD1 (0.47) | NOD1SLC6A5FOLH1ITGB3ITGA2B | |
| SCHEMBL6688677 | 0.95 | NOD1 (0.47) | NOD1SLC6A5FOLH1ITGB3ITGA2B | |
| SCHEMBL6688681 | 0.95 | NOD1 (0.47) | NOD1SLC6A5FOLH1ITGB3ITGA2B | |
| SCHEMBL30915502 | 0.94 | SLC6A5 (0.56) | NOD1SLC6A5EPHX1TLR2FOLH1 | |
| SCHEMBL7803299 | 0.94 | SLC6A5 (0.56) | NOD1SLC6A5EPHX1TLR2FOLH1 | |
| SCHEMBL7804980 | 0.94 | SLC6A5 (0.56) | NOD1SLC6A5EPHX1TLR2FOLH1 | |
| SCHEMBL7797291 | 0.94 | SLC6A5 (0.56) | NOD1SLC6A5EPHX1TLR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030214-B2 | Ureins derived from α, ω, diamino acids and process for their preparation | SOLVAY (SOCIETE ANONYME) (BE) | 2006-04-18 | — | — | US | disclosed |
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | CALLENS ROLAND (BE) | 2002-05-16 | — | — | US | disclosed |
| US-6310178-B1 | AS THE N-TERMINAL RESIDUE OF BIOLOGICALLY ACTIVE PEPTIDES, E.G, THYROTROPIN RELEASING HORMONE (BY REPLACING THE N-TERMINAL PYROGLUTAMYL GROUP); IMPARTING INCREASED RESISTANCE TO PROTEOLYTIC DIGESTION | SOLVAY, S.A. (BE) | 2001-10-30 | — | — | US | disclosed |
| EP-0629612-B1 | Process for the preparation of ureas derived from alpha, omega-diaminoacids | SOLVAY (BE) | 1999-12-01 | — | — | EP | disclosed |
| EP-0922696-A2 | Urea derivatives of alpha, omega-diaminoacids and peptides | SOLVAY (Société Anonyme) (BE) | 1999-06-16 | — | — | EP | disclosed |
| EP-0629612-A1 | Ureas derived from alpha, omega-diaminoacids and process for their preparation | SOLVAY (Société Anonyme) (BE) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058784-A1 | Ureins derived from alpha, omega, -diamond acids and process for their preparation | UPP1, URB2, UFM1 | NOD1 2264/4885SLC6A5 4769/4885EPHX1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.